LumenEye used in CPI colitis triage to reduce endoscopy demand and accelerate treatment decisions.
This BSG 2023 abstract describes a case series evaluating the use of the LumenEye® digital rectoscope in cancer patients presenting with diarrhoea following immune checkpoint inhibitor therapy. These patients are often suspected of having immune-mediated colitis, a side effect requiring rapid diagnosis and intervention.
LumenEye was deployed in both outpatient and inpatient settings, enabling immediate visual assessment of the rectum. The device helped identify mucosal inflammation, allowing clinicians to confirm or rule out colitis without delay. In several cases, LumenEye use reduced the need for flexible sigmoidoscopy, expedited treatment initiation, and improved resource use.
The study highlights how digital proctoscopy can offer a rapid, safe, and cost-effective triage tool in immuno-oncology care pathways.
